Research Article
Print
Research Article
Comparative molecular docking and ADMET profiling of niclosamide and berberine against multiple Helicobacter pylori enzymatic targets
expand article infoCatalina Danila‡, Lucian Faur‡, Lucian Mocan§, Daniela Simona Cavalu‡
‡ University of Oradea, Oradea, Romania
§ “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Open Access

Abstract

Objectives: The eradication of Helicobacter pylori is often challenged by antimicrobial resistance, adherence issues, and regional variation in treatment outcomes. As a hypothesis-generating step, early-stage pharmaceutical prioritization can identify repurposed or bioactive structures for experimental testing. This study compared the docking profiles of niclosamide and berberine against selected H. pylori enzymatic targets, using levofloxacin as a clinically relevant antibacterial comparator.

Materials and methods: Blind molecular docking was performed against H. pylori urease, DNA gyrase subunit A, and shikimate kinase. Top-ranked poses were described using Vina-type scores, three-dimensional binding inspection, two-dimensional residue-interaction mapping, and absorption, distribution, metabolism, excretion, and toxicity (ADMET)/drug-likeness predictions. Docking scores were treated as ranking scores rather than binding free energies or experimental affinity constants.

Results: In this small docking matrix, berberine produced the most negative descriptive mean score, while niclosamide produced one of the two top-ranked urease poses. These score differences do not establish differences in binding affinity, target engagement, or biological potency. Levofloxacin was included as a clinically relevant comparator. Predicted ADMET descriptors highlighted compound-specific questions related to exposure, solubility, and formulation but were not interpreted as evidence of therapeutic suitability.

Conclusion: The integrated analysis prioritizes niclosamide and berberine for further anti-H. pylori investigation without demonstrating binding, enzyme inhibition, antibacterial activity, or therapeutic efficacy. The predicted poses and scores, considered alongside existing experimental literature and predicted ADMET descriptors, define testable hypotheses for urease inhibition assays, minimum inhibitory concentration (MIC) determination, cytotoxicity testing, and formulation-focused studies.

Keywords

ADMET, berberine, DNA gyrase, drug repurposing, Helicobacter pylori, levofloxacin, molecular docking, niclosamide, pharmaceutical prioritization, shikimate kinase

Introduction

Helicobacter pylori remain one of the most clinically important bacterial pathogens in gastroenterology because of its high global prevalence and its established association with chronic active gastritis, peptic ulcer disease, gastric mucosal atrophy, intestinal metaplasia, dysplasia, and gastric adenocarcinoma (International Agency for Research on Cancer 1994; Uemura et al. 2001; Wroblewski et al. 2010; Correa and Piazuelo 2012; Sugano et al. 2015; Hooi et al. 2017; Ford et al. 2020; Sugano et al. 2023). Beyond its role as an infectious agent, H. pylori is classified by the International Agency for Research on Cancer as a Group 1 human carcinogen, placing its eradication within both gastroenterological and cancer prevention frameworks (International Agency for Research on Cancer 1994; Sugano et al. 2023).

The biological and clinical significance of this classification is supported by prospective cohort evidence linking H. pylori infection to the subsequent development of gastric cancer, the Correa multistep model of gastric carcinogenesis, and mechanistic evidence demonstrating that bacterial virulence factors, chronic inflammation, host susceptibility, and environmental factors influence disease progression (Uemura et al. 2001; Wroblewski et al. 2010; Correa and Piazuelo 2012; Sugano et al. 2015).

The Kyoto global consensus further established H. pylori gastritis as an infectious disease that should be diagnosed and treated, while meta-analytic evidence indicates that eradication therapy can reduce the subsequent risk of gastric cancer in appropriate populations (Sugano et al. 2015; Ford et al. 2020). Collectively, this carcinogenic and preventive relevance provides a strong rationale for continued pharmaceutical research into novel and repurposed compounds with potential anti-H. pylori activity.

International and regional clinical practice guidelines serve as a guide for anti-H. pylori treatment; however, there is no universal regimen applicable to all patients. The Maastricht VI/Florence Consensus Report emphasizes local antibiotic resistance patterns, prior antibiotic exposure, treatment history, and susceptibility testing when available, providing an important framework for treatment selection in Europe and other international settings (Malfertheiner et al. 2022). The 2024 American College of Gastroenterology guideline in North America advises against empirical proton pump inhibitor (PPI)-clarithromycin triple therapy unless clarithromycin susceptibility has been established and suggests 14-day optimized bismuth quadruple therapy as the preferred empirical regimen for treatment-naïve adults when antibiotic susceptibility is unknown (Chey et al. 2024).

Other recommendations, such as the Toronto Consensus and the World Gastroenterology Organization guidelines, also emphasize treatment duration, local resources, regional resistance trends, and the diminishing efficacy of empirical clarithromycin-based therapy (Fallone et al. 2016; Katelaris et al. 2023).

The American Gastroenterological Association Clinical Practice Update cited here addresses the diagnosis and management of atrophic gastritis, including H. pylori-associated atrophic gastritis and the importance of identifying and treating the infection (Shah et al. 2021). Global monitoring data demonstrate that resistance to levofloxacin, metronidazole, and clarithromycin can significantly reduce the efficacy of empirical eradication regimens, further supporting a resistance-aware strategy (Savoldi et al. 2018).

Consequently, contemporary H. pylori management relies on guideline-directed combination therapy tailored to antibiotic resistance patterns, previous treatment exposure, and, whenever available, susceptibility testing.

The pharmaceutical relevance of H. pylori is therefore not limited to classical antibiotics. In the post-resistance era, computational repurposing and early absorption, distribution, metabolism, excretion, and toxicity (ADMET)-based prioritization can help identify compounds worth testing in focused urease, minimum inhibitory concentration (MIC), synergy, cytotoxicity, and resistance-development assays.

Niclosamide was selected as a repurposed anthelmintic with reported anti-H. pylori activity and broad anti-infective interest (Tharmalingam et al. 2018). Berberine was selected as a natural isoquinoline alkaloid with documented antibacterial potential and increasing interest in H. pylori-related applications (Guo et al. 2024). Levofloxacin was included as a clinically relevant comparator rather than as a novel candidate. The purpose of the present study was to integrate a uniform multitarget docking matrix, interaction mapping, and cautious ADMET interpretation to prioritize these molecules for further validation. The novelty lies in this comparative three-target framework and in the proposed, explicitly hypothesis-generating enzyme-level interpretations, not in identifying niclosamide or berberine as previously unrecognized anti-H. pylori compounds.

The selection of niclosamide was supported by experimental data rather than docking convenience alone. In an in vitro and infection-model study, niclosamide inhibited H. pylori strain 60190 with an MIC of 0.25 µg/mL, remained active at acidic pH, showed partial synergy with metronidazole and proton pump inhibitors, reduced H. pylori adhesion/invasion of gastric epithelial cells by approximately 3 log CFU, did not generate detectable resistance after prolonged exposure, and was active in a Galleria mellonella–H. pylori infection model (Tharmalingam et al. 2018). These findings provide a biological rationale for investigating whether predicted binding to urease, DNA gyrase A, or shikimate kinase could complement previously proposed membrane/proton-motive-force-related mechanisms.

Although its mechanism and pharmacological limitations are still incompletely defined, berberine was chosen because preclinical and clinical observations point to anti-H. pylori relevance. A 14-day quadruple regimen containing berberine achieved eradication rates of 90.1% by intention-to-treat analysis and 91.3% by per-protocol analysis, according to a randomized phase IV trial, with non-inferiority to a quadruple regimen containing bismuth in the Chinese population studied (Zhang et al. 2017). In addition to improving ulcer healing and reducing adverse events, adding berberine to standard triple therapy enhanced eradication compared with standard triple therapy alone (risk ratio [RR] 1.22; 95% confidence interval [CI] 1.16–1.27), according to a later systematic review and meta-analysis (Hu et al. 2020).

Evidence on berberine, however, is not consistently favorable in every formulation and therapeutic setting. Rather than showing definite superiority, a randomized trial of triple therapy incorporating berberine reported similar eradication rates among the groups under investigation (Chen et al. 2023). Furthermore, reported berberine MIC values against H. pylori vary greatly depending on strain and methodology, ranging from low microgram-per-milliliter values in some systems to significantly higher concentrations in others, according to recent antimicrobial studies (Yang et al. 2025). Therefore, rather than assuming clinical efficacy, the present study examines whether berberine exhibits acceptable early ADMET characteristics and plausible enzyme-target interactions that could justify additional experimental testing.

Molecular docking, ADMET profiling, virtual screening, network pharmacology, and experimental follow-up have increasingly been integrated in recent anti-H. pylori research. This body of work is relevant because it shows that computational studies can be useful when they are presented as rational early-stage prioritization rather than as evidence of clinical effectiveness. By combining residue-level interaction maps, a uniform multitarget docking matrix, literature-guided ligand selection, and pharmacokinetic interpretation, the present study follows that approach. Recent articles in Pharmacia likewise illustrate a spectrum of computational workflows, including molecular docking of ginger-derived bioactive compounds, docking-based assessment of candidate inflammatory mediators, pharmacophore-guided virtual screening with molecular dynamics, and docking followed by molecular dynamics stability analysis (Alamsyah et al. 2023; Musfiroh et al. 2023; Fakih et al. 2024; Ramadhan et al. 2026).

Table 1 summarizes representative anti-H. pylori studies based on molecular docking, ADMET/drug-likeness, virtual screening, molecular dynamics, or experimental follow-up. The aim is not to provide an exhaustive review but to define the level of evidence and the methodological niche of the present manuscript.

Table 1.

Representative anti-H. pylori computational and integrated studies used to position the present pharmaceutical prioritization workflow.

Study Compounds/source H. pylori target(s) or readout Computational/experimental level How it supports the present manuscript
(Fong et al. 2019) Oroxindin, rosmarinic acid, and verbascoside, alone or combined with antibiotics Urease, shikimate kinase, aspartate-semialdehyde dehydrogenase; MIC and checkerboard readouts Docking, drug-likeness filtering, MIC testing, and synergy analysis Strong precedent for using docking/drug-likeness as a rational screening step before microbiological validation of adjuvant anti-H. pylori candidates.
(Al Tawalbeh et al. 2022) Selected phytochemicals; terpineol highlighted H. pylori urease and whole-cell anti-H. pylori readouts Docking, in vitro urease inhibition, MIC, and combination testing with metronidazole Shows that urease-oriented docking can be used when linked to pharmacological interpretation and experimental follow-up.
(Kanji and Mondal 2024) Glycyrrhizin, cinnamaldehyde, and coumarin with antibiotic comparators BabA, SabA, CagA, VacA, and urease Molecular docking plus ADMET/drug-compatibility assessment Recent precedent for H. pylori docking/ADMET prioritization; supports the acceptability of a computational screening format when limitations are explicit.
(Valenzuela-Hormazabal et al. 2024) Virtual-screening hits selected as urease-inhibitor candidates H. pylori urease Pharmacophore/structure-based virtual screening, ADME filtering, molecular dynamics, and MM-GBSA Higher-complexity benchmark. It clarifies that the present manuscript is broader in target scope but more preliminary because it does not include MD/MM-GBSA.
(Noori Goodarzi et al. 2024) StreptomeDB-derived candidate molecules DAH7PS, a shikimate-pathway protein selected from a target-discovery pipeline Core-proteome target selection, homology modeling, AutoDock Vina docking, MD, and ADMET Supports shikimate-pathway proteins as rational H. pylori antibacterial targets and validates target-prioritization logic.
(Tharmalingam et al. 2018) Niclosamide and related anthelmintics Whole-cell H. pylori growth and host-cell adhesion/invasion models Experimental anti-H. pylori study, not docking-centered Provides direct biological rationale for including niclosamide as a repurposing candidate rather than as an arbitrary docking ligand.
(Guo et al. 2024) Berberine derivatives discovered through a deep-learning workflow Drug-susceptible and drug-resistant H. pylori strains; OMP-related targets AI-guided discovery plus microbiological, pharmacokinetic, and target-validation experiments Supports berberine-derived scaffolds as a credible anti-H. pylori chemical space and strengthens the mechanistic interest in berberine.
(Cardos et al. 2026) Phenolic/flavonoid constituents of Viscum album L. Urease and shikimate-pathway enzymes, among others Docking plus interaction mapping and in vitro anti-urease/anti-virulence readouts Shows that enzyme-focused H. pylori docking can be integrated with natural-product pharmaceutical exploration.
(Gao et al. 2024) Fisetin, quercetin, and geniposide H. pylori HtrA protease plus bacterial growth readouts Docking, molecular dynamics, and experimental validation of enzyme inhibition and anti-H. pylori growth effects Illustrates a validation pathway that future work could follow after the prioritization generated in the present study.
Present study Niclosamide, berberine, and levofloxacin comparator Urease, DNA gyrase A, and shikimate kinase CB-Dock2/Vina docking, three-dimensional inspection, two-dimensional interaction maps, descriptive score summaries, and predicted ADMET profiling Provides a compact comparative multitarget, hypothesis-generating framework; it does not validate binding or mechanism and requires biochemical and microbiological testing.

Materials and methods

Study design

Blind molecular docking, interaction mapping, and ADMET-based prioritization were combined in this in silico original research study. The procedure created a 3 × 3 descriptive docking matrix comparing three ligands across three molecular targets associated with H. pylori. The analysis was not intended to replace biochemical or microbiological validation; it was a hypothesis-generating screening phase.

Target selection and receptor preparation

Shikimate kinase, DNA gyrase subunit A, and H. pylori urease were selected to represent complementary biological functions: an essential microbial biosynthetic pathway, DNA topology, and acid adaptation and colonization, respectively. Protein Data Bank (PDB) 1E9Y was chosen for urease because of its established biological relevance and structurally defined nickel-containing architecture. PDB 1ZUH was used for shikimate kinase because it is an experimentally determined H. pylori structure. DNA gyrase subunit A was represented by the AlphaFold model linked to UniProt P48370 because a suitable experimental structure for the planned blind-docking comparison was unavailable. Biological relevance does not by itself establish druggability; accordingly, these proteins were treated as plausible test targets, and tractability was not assumed from docking alone.

Metal components important for urease stability were retained, non-essential water molecules were removed, and protein files were visually examined. This step was performed to avoid disruption of the nickel-dependent architecture of urease.

Ligand selection and preparation

Levofloxacin, berberine, and niclosamide were the ligands under investigation. Levofloxacin was used as a comparator with established clinical significance in H. pylori rescue therapy, berberine as a naturally occurring bioactive alkaloid, and niclosamide as a repurposing candidate. Three-dimensional ligand structures were created or acquired in CB-Dock2-compatible formats and examined for structural consistency before submission. Berberine was represented in its permanent quaternary ammonium form. Alternative protonation, tautomeric, and ionization microstates were not systematically enumerated for niclosamide or levofloxacin; this preparation constraint is acknowledged because ligand state can influence predicted poses and scores.

Accordingly, the ligand panel was guided by the literature. Levofloxacin was retained only as a clinically recognized antibacterial comparator, while niclosamide and berberine were given priority because of their prior anti-H. pylori-related data. The goal of the docking experiment was not to replicate the entire clinical pharmacology of eradication therapy but rather to investigate possible enzyme-level engagement.

Comparator rationale and docking-validation scope

Because levofloxacin has been linked to bacterial topoisomerase targeting and is used in rescue anti-H. pylori regimens, it was included as a therapeutically relevant comparator. It was not used to determine the clinical superiority of the repurposed compounds and was not considered a novel candidate. Since the goal was to compare two non-classical structures with a clinically well-known antibacterial reference rather than to replicate all therapeutic classes, clarithromycin and metronidazole were excluded from the docking matrix.

All ligands were assessed across the same target set, residue-level interaction maps were created, and the best-ranked poses were visually examined in three dimensions. These consistency checks aid interpretation but do not constitute formal validation of the docking protocol. No cognate-ligand redocking, receiver operating characteristic benchmarking against known binders and nonbinders, or prospective experimental validation was performed; therefore, pose accuracy and enrichment cannot be claimed. Docking was performed using CB-Dock2, an automated blind-docking server that combines cavity detection, docking, and pose ranking (Trott and Olson 2010; Forli et al. 2016; Liu et al. 2022). For each receptor-ligand pair, the top-ranked pose according to the Vina score was retained. Vina-type outputs were interpreted as relative docking scores, not experimental binding constants or binding free energies. Discovery Studio Visualizer was used only to inspect three-dimensional poses and residue-level interaction maps. The workflow is therefore suitable for hypothesis generation, not for demonstrating enzyme inhibition or antibacterial activity.

Reproducibility and software details

Protein structures were identified by the PDB and UniProt identifiers reported above, and ligand structures were obtained from PubChem. CB-Dock2 (Liu et al. 2022), PubChem, and SwissADME were accessed in June 2026. The server-side CB-Dock2 build number was not displayed to the user. Discovery Studio Visualizer (BIOVIA, Dassault Systèmes) was used for three-dimensional inspection and two-dimensional interaction diagrams; the locally installed build metadata were not retained. Original docking outputs, interaction files, and figure panels were retained. These disclosures identify the available reproducibility information without implying unavailable version precision.

Docking-score and statistical interpretation

Vina-type outputs were retained in their native scoring units and were not converted to Ki or pKi. A docking score is an empirical ranking function and is not the binding free energy, delta G binding = G complex – (G free protein + G free ligand). Docking does not determine all free-state and solvent contributions required by this thermodynamic relationship; a favorable score can therefore occur for a nonbinder. Because the matrix contained only three ligands and three targets, no inferential statistical test was used. Means and standard deviations are reported only as descriptive summaries of this specific matrix and cannot support population-level or biological inference.

ADMET and drug-likeness assessment

Molecular weight, topological polar surface area, lipophilicity, hydrogen-bond donors and acceptors, predicted gastrointestinal absorption, blood–brain barrier permeation, Lipinski rule-of-five compliance, bioavailability score, and medicinal-chemistry alerts were obtained from SwissADME-type workflows (Lipinski et al. 2001; Veber et al. 2002; Daina et al. 2017). These are computational descriptors, not measurements of exposure, bioavailability, safety, or therapeutic suitability. They were used to flag formulation and pharmacokinetic questions rather than to validate or upgrade the docking ranking.

Results

The complete docking matrix is presented in Table 2. Berberine and niclosamide shared the most negative score against urease (–8.5 kcal/mol), and berberine also produced the most negative score against DNA gyrase A (–8.5 kcal/mol). Shikimate kinase scores were less negative across this matrix. These numerical differences were used only to describe the ranking generated by the selected workflow; they do not establish differences in affinity, inhibition, or antibacterial potency. The ligand–target score pattern is shown in Fig. 1.

Figure 1. 

Heatmap of the top-ranked Vina score for each ligand–target combination. More negative values indicate lower scores within this workflow and should not be interpreted as experimental binding energies.

Table 2.

Molecular docking scores for the three ligand–target combinations.

Target Structure/model Ligand Cavity Vina score (kcal/mol)
Urease PDB 1E9Y Niclosamide C1 –8.50
Urease PDB 1E9Y Berberine C1 –8.50
Urease PDB 1E9Y Levofloxacin C1 –7.90
DNA gyrase A AlphaFold/UniProt P48370 Niclosamide C1 –7.80
DNA gyrase A AlphaFold/UniProt P48370 Berberine C2 –8.50
DNA gyrase A AlphaFold/UniProt P48370 Levofloxacin C3 –7.50
Shikimate kinase PDB 1ZUH Niclosamide C2 –6.90
Shikimate kinase PDB 1ZUH Berberine C1 –7.30
Shikimate kinase PDB 1ZUH Levofloxacin C2 –7.00

Across the three targets, the descriptive mean scores were –8.10 ± 0.69 kcal/mol for berberine, –7.73 ± 0.80 kcal/mol for niclosamide, and –7.47 ± 0.45 kcal/mol for levofloxacin. Descriptive target means were –8.30 ± 0.35 kcal/mol for urease, –7.93 ± 0.51 kcal/mol for DNA gyrase A, and –7.07 ± 0.21 kcal/mol for shikimate kinase. Given the 3 × 3 matrix and the non-independent target–ligand structure, inferential testing was not considered informative and was removed. Fig. 2 presents these means only as a visual summary of the current docking runs. Representative three-dimensional poses and target-specific two-dimensional maps document the selected predictions but do not validate them.

Figure 2. 

Descriptive mean docking scores across the three selected H. pylori targets. The figure summarizes this 3 × 3 matrix and does not establish an affinity or potency ranking.

Representative three-dimensional predicted poses were included to display the orientations selected by the docking algorithm before residue-level description by two-dimensional maps. These poses are shown in Fig. 3, while the principal modeled contacts and interaction classes are summarized in Table 3.

Figure 3. 

Representative three-dimensional predicted poses selected by the docking workflow. A. Niclosamide with H. pylori urease; B. Berberine with DNA gyrase subunit A; and C. berberine with shikimate kinase. The panels record modeled orientations and contacts; they do not validate binding or pose accuracy.

Table 3.

Main residues and interaction classes observed in the best-ranked complexes.

Target Ligand Main residues Main interaction classes
Urease Niclosamide VAL B:473, TYR B:475, PRO B:472, MET A:12, TYR B:474, ALA A:37, LYS B:445, PHE B:441, VAL A:33 Conventional hydrogen bonds, hydrophobic contacts, pi-related contacts, van der Waals
Urease Berberine LEU A:13, ALA A:16, ALA A:37, VAL A:33, VAL A:36, LYS B:445, PHE B:441, TYR A:32, GLN B:471, VAL B:473, SER B:438 Pi-alkyl, pi-sigma, hydrophobic contacts, van der Waals
Urease Levofloxacin LYS B:445, VAL A:33, ALA A:37, GLN B:471, TYR B:475, TYR B:474, TYR A:32, VAL B:473, VAL A:36, PRO B:472, LEU A:13, ALA A:16, ALA B:150, SER B:567, ILE B:568 Hydrogen bonds, van der Waals, pi-alkyl, one unfavorable positive-positive contact
DNA gyrase A Niclosamide VAL A:702, ASN A:806, LYS A:654, TYR A:804, VAL A:651, LYS A:619 Hydrogen bonds, pi-pi stacked, pi-sigma, alkyl and pi-alkyl
DNA gyrase A Berberine PHE A:549, PRO A:809, ILE A:546, TYR A:525, SER A:537 Pi-pi stacked, pi-T-shaped, alkyl, pi-alkyl, carbon-hydrogen bond
DNA gyrase A Levofloxacin ASP A:91, ARG A:95, GLN A:98, SER A:115, ALA A:121, GLN A:269 Hydrogen bonds, carbon-hydrogen, halogen, attractive charge, one unfavourable positive-positive contact
Shikimate kinase Niclosamide ASP A:31, ASP A:33, MET A:34, VAL A:44, ARG A:45, GLY A:79, THR A:78, MET A:10, SER A:15, SER A:12, GLY A:13, LYS A:14, GLY A:11, PHE A:9, ARG A:107, SER A:43 Hydrogen bonds, carbon-hydrogen, van der Waals, alkyl, pi-alkyl, pi-anion
Shikimate kinase Berberine PHE A:129, LEU A:104, PHE A:9, ARG A:132, GLY A:80, GLY A:81 Hydrogen bonds, pi-cation, pi-T-shaped, alkyl and pi-alkyl
Shikimate kinase Levofloxacin SER A:15, VAL A:44, ASP A:31, ASP A:33, LYS A:14, SER A:12, GLY A:11, GLY A:13 Hydrogen bonds, attractive charge, alkyl, carbon-hydrogen, positive-positive contact

Two-dimensional interaction-map analysis

The chosen best-ranked poses were reorganized into target-specific two-dimensional interaction maps to supplement the numerical docking matrix, the representative three-dimensional binding poses, and the residue summary in Table 3. This format makes it possible to compare the interaction patterns of levofloxacin, berberine, and niclosamide within the same receptor context. The two-dimensional diagrams served as visual support for the plausibility and chemical interpretation of the chosen docking poses rather than as a separate scoring mechanism. The corresponding urease, DNA gyrase A, and shikimate kinase maps are presented in Figs 4, 5, 6, respectively.

Figure 4. 

Compact two-dimensional Discovery Studio Visualizer interaction maps for niclosamide, berberine, and levofloxacin docked against H. pylori urease. Panels A–C correspond to niclosamide, berberine, and levofloxacin, respectively; the maps show hydrogen-bond, hydrophobic, pi-related, and van der Waals contacts supporting the selected docking poses.

Figure 5. 

Compact two-dimensional interaction maps for niclosamide, berberine, and levofloxacin docked against H. pylori DNA gyrase A. Panels A–C correspond to niclosamide, berberine, and levofloxacin, respectively. The maps illustrate the residue-level interaction patterns supporting the selected docking poses.

Figure 6. 

Compact two-dimensional interaction maps for niclosamide, berberine, and levofloxacin docked against H. pylori shikimate kinase. Panels A–C correspond to niclosamide, berberine, and levofloxacin, respectively; the maps provide residue-level support for interpretation of the docking scores.

Overall, the interaction maps show that poses with the same Vina score may contain different predicted contact patterns. This was especially noticeable for urease, where berberine and niclosamide had different dominant interaction classes despite identical scores. The maps are descriptive visualizations of predicted poses and were not treated as independent evidence of binding or biological activity (Table 4).

Table 4.

ADMET and drug-likeness interpretation.

Ligand MW (g/mol) TPSA (A2) Consensus logP GI absorption BBB permeation Lipinski violations Bioavailability score Integrated interpretation
Niclosamide 282.12 49.33 3.78 High Yes 0 0.55 Predicted descriptors do not establish exposure or suitability. Poor solubility and limited absorption require formulation and local-exposure studies.
Berberine 336.36 40.80 approx. 2.8–3.0 High Yes/predicted possible 0 0.55 Predicted GI absorption and BBB permeation do not establish suitability; complex, formulation-dependent pharmacokinetics require experimental confirmation.
Levofloxacin 361.37 73.32 approx. 0.8–1.3 High No/limited 0 0.55 Comparator only; predicted descriptors add no evidence of efficacy or safety beyond established pharmacology and resistance data.

Urease: All three top-ranked poses occupied the same predicted cavity region. Niclosamide and berberine produced the same score (–8.5 kcal/mol), but this numerical equality does not demonstrate equal affinity or inhibition. Berberine’s predicted pose contained mainly pi-associated and hydrophobic contacts, whereas the niclosamide pose contained hydrogen-bonding, hydrophobic, and aromatic contacts. Levofloxacin produced a score of –7.9 kcal/mol with a broad predicted residue-contact pattern.

DNA gyrase subunit A: Berberine produced the most negative score in this three-ligand comparison (–8.5 kcal/mol), with a predicted pose containing aromatic contacts involving PHE A:549 and TYR A:525. Niclosamide scored –7.8 kcal/mol and levofloxacin –7.5 kcal/mol; these differences do not establish affinity or potency. Interpretation is further limited because the receptor was not an experimentally resolved cocrystallized DNA gyrase–drug complex, and fluoroquinolone action in vivo depends on the ternary DNA–enzyme–drug context.

Shikimate kinase: Scores against shikimate kinase were less negative than those for urease and DNA gyrase A in this matrix. Berberine ranked first (–7.3 kcal/mol), followed by levofloxacin (–7.0 kcal/mol) and niclosamide (–6.9 kcal/mol), but the small differences should not be interpreted as potency differences. Shikimate kinase remains conceptually relevant because the classical shikimate biosynthetic pathway is present in many microorganisms and plants but is not encoded as a corresponding pathway in humans, making its enzymes attractive, though not automatically tractable, antimicrobial targets.

Discussion

Using levofloxacin as a comparator, this work offers a pharmacologically focused in silico prioritization of niclosamide and berberine against three selected H. pylori targets. The primary outcome is the creation of a ranked shortlist for experimental validation rather than the discovery of a definitive inhibitor. This distinction is important because molecular docking analyzes the plausibility of ligand–target complementarity under simplified conditions, whereas antibacterial efficacy depends on absorption, local exposure, bacterial physiology, resistance mechanisms, and toxicity.

Positioning relative to eradication therapy and prior experimental data

The current computational study should not be interpreted as suggesting an antibiotic substitute but rather in the context of guideline-directed eradication therapy. A resistance-aware strategy is supported by the Maastricht VI/Florence Consensus Report, the American College of Gastroenterology (ACG) guideline, and the American Gastroenterological Association (AGA) Clinical Practice Update. Local resistance, prior antibiotic exposure, susceptibility testing when available, appropriate duration, and adherence should all be taken into account when choosing a regimen (Shah et al. 2021; Malfertheiner et al. 2022; Chey et al. 2024). Docking/ADMET research can be useful within this framework if it is presented as a prioritization step that identifies compounds for further biochemical and microbiological confirmation.

Existing experimental evidence shows that niclosamide can inhibit H. pylori growth under the tested conditions, retain activity at acidic pH, affect adhesion/invasion, and show no readily detectable resistance during serial exposure experiments (Tharmalingam et al. 2018). The present docking results neither reproduce those findings nor identify their mechanism. They generate a separate, target-oriented hypothesis that urease and the other selected enzymes could be tested experimentally; the predicted poses cannot establish that these proteins mediate the previously observed antibacterial effects.

Meta-analytic and clinical data indicate that berberine-containing combination regimens may improve or achieve clinically relevant eradication outcomes in some settings (Zhang et al. 2017; Hu et al. 2020), whereas other results do not demonstrate clear superiority (Chen et al. 2023). These clinical observations cannot validate the enzyme poses predicted here, and the docking results cannot identify the mechanism responsible for reported clinical or antibacterial effects. Berberine should therefore be viewed as a scaffold for mechanistic and formulation-focused testing, not as a docking-supported monotherapy.

The inclusion of urease, DNA gyrase A, and shikimate kinase was intended to cover complementary biological levels: acid adaptation and colonization, DNA replication/topology, and the classical shikimate biosynthetic pathway, which is not encoded as a corresponding pathway in humans. Recent anti-H. pylori work using natural compounds and in silico enzyme targeting supports this type of multitarget framework when computational findings are subsequently connected to biochemical or microbiological validation (Noori Goodarzi et al. 2024). In the present study, the defensible interpretation is candidate prioritization rather than therapeutic prediction.

The most pharmacologically intuitive results are those for urease. All three ligands occupied a predicted urease cavity with favorable or moderate scores. Urease is a nickel-dependent virulence enzyme that is necessary for adaptation to the gastric niche. Although berberine and niclosamide had the same urease score, their interaction maps revealed distinct stabilization patterns. This observation demonstrates that equal Vina scores should not be interpreted as mechanistically identical binding modes, which supports the use of two-dimensional Discovery Studio Visualizer diagrams in the main article.

The results for DNA gyrase A need to be interpreted more cautiously. Although levofloxacin is clinically associated with bacterial topoisomerase inhibition, its actual mechanism involves the enzyme–DNA complex and quinolone resistance-determining regions. Thus, the pharmacodynamic context of fluoroquinolone action cannot be properly replicated by the isolated DNA gyrase A model. However, berberine demonstrated a favorable predicted interaction driven by hydrophobic and aromatic contacts, which is in line with the increased interest in anti-H. pylori candidates derived from berberine (Tharmalingam et al. 2018).

The shikimate kinase scores were less negative than those for the other targets in this matrix. The enzyme belongs to the classical shikimate pathway, which is present in many microorganisms and plants but is not encoded as a corresponding pathway in humans; this biological distinction motivates testing but does not establish tractability. The small score differences do not show that any compound inhibits shikimate kinase. For the present ligands, this target should therefore be considered a lower-priority experimental hypothesis rather than a predicted mechanism.

Predicted ADMET descriptors did not validate the docking ranking. Berberine’s quaternary cationic structure, formulation-dependent exposure, and known pharmacokinetic complexity require experimental assessment. Niclosamide’s limited solubility and exposure likewise make formulation-oriented work important; its repurposing interest arises primarily from prior experimental anti-H. pylori evidence, not from a small difference in mean docking score. Levofloxacin was used only as a clinically interpretable comparator.

Pharmaceutical relevance of the prioritization approach

From a pharmacological standpoint, the value of the analysis is the joint description of predicted poses, literature-based biological plausibility, and developability questions, not the demonstration of target engagement. Berberine had the most negative descriptive mean score, but direct translation is limited by its quaternary cationic structure and formulation-dependent exposure. Niclosamide remains a logical choice for targeted anti-H. pylori testing because of prior experimental evidence and a top-ranked urease pose, not because binding was established. Levofloxacin served as a clinical comparator rather than a lead candidate.

Initial urease-inhibition tests, broth microdilution or agar-dilution MIC testing against reference and clinical H. pylori strains, checkerboard assays using standard antibiotics, and cytotoxicity testing on gastric epithelial cell models are practical next steps. Molecular dynamics and post-docking free-energy analyses could be considered for experimentally supported complexes. The resulting pharmaceutical message is deliberately restricted: (i) docking scores provide a workflow-specific ranking, not proof of binding; (ii) interaction maps describe the residue-level contacts of predicted poses; and (iii) ADMET descriptors flag properties requiring experimental pharmacokinetic and formulation assessment. None of these outputs demonstrates therapeutic suitability.

This integrated interpretation is particularly suitable for further laboratory work, including urease inhibition assays, MIC determination against H. pylori strains, cytotoxicity screening, and, if results justify it, molecular dynamics simulations.

Integrated prioritization was expressed narratively rather than in a separate redundant table. Within this limited matrix, berberine produced the most consistent score pattern, niclosamide remained the clearest repurposing candidate for urease-focused testing because of prior experimental evidence, and levofloxacin served as a clinically useful comparator. This ordering is a pragmatic experimental-prioritization proposal and not a validated affinity or potency ranking.

Representative three-dimensional poses supplement the numerical scores by showing the orientations selected by the docking algorithm. The urease and DNA gyrase examples display geometrically plausible predicted accommodation, while the two-dimensional diagrams describe the associated modeled contacts. Visual plausibility is not validation and does not establish affinity. The combined representation is useful only as a transparent record of the hypotheses selected for future testing.

The simultaneous integration of three target classes—urease, a virulence/adaptation enzyme; DNA gyrase A, a replication-related target; and shikimate kinase, an enzyme involved in a specific metabolic pathway—is a key aspect of this work. Compared with a single-protein docking experiment, this multitarget approach provides more information and is more consistent with early-stage pharmacological prioritization. The method is especially suitable for natural and repurposed compounds, for which both biological plausibility and ADMET feasibility should be considered before investing in experiments.

Therefore, the comparative value of the manuscript does not depend on the claim that docking predicts clinical response. Using a shared target panel and a uniform ADMET interpretation, it provides an organized ranking of mechanistically plausible compounds that already have antibacterial or anti-H. pylori relevance. Using computational research to reduce the experimental search space before costly microbiological or enzymatic testing, this framework supports early-stage pharmacological screening.

Limitations

This research is a preliminary, hypothesis-generating prioritization study. A docking score is an empirical score for a modeled complex, not the binding free energy. Thermodynamically, delta G binding = G complex – (G free protein + G free ligand); the present workflow does not determine the free-state, solvation, desolvation, and entropic contributions needed for that quantity. A ligand with a favorable docked-complex score may therefore still prefer solution, self-associate, or fail to bind, and virtual-screening workflows can produce substantial false-positive rates (Ivanov 2026a, 2026b). No formal redocking or enrichment validation, MD simulations, molecular mechanics/generalized Born surface area (MM/GBSA), or molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) analyses were performed. Receptor flexibility, solvent effects, alternative protonation microstates, and induced fit were not fully modeled. The DNA gyrase A model also does not reproduce the DNA–enzyme–quinolone ternary complex. Consequently, the study demonstrates neither binding, target engagement, enzyme inhibition, bacterial killing, nor therapeutic efficacy. The proposed next steps are urease-inhibition testing, MIC and minimum bactericidal concentration (MBC) determination in reference and clinical H. pylori strains, combination testing, cytotoxicity assays, and, if justified by experimental results, MD and post-docking free-energy analyses.

Conclusion

In this comparative in silico study, berberine produced the most consistent descriptive score pattern across H. pylori urease, DNA gyrase A, and shikimate kinase, while niclosamide combined a top-ranked urease pose with the clearest prior experimental repurposing rationale. Docking scores, three-dimensional poses, two-dimensional interaction maps, and predicted ADMET descriptors were used to prioritize hypotheses, not to demonstrate binding, target engagement, enzyme inhibition, antibacterial activity, or therapeutic efficacy. The results justify focused experimental testing of berberine and niclosamide, with conclusions restricted to prioritization for urease assays, MIC testing, cytotoxicity assessment, and formulation-oriented investigation.

References

  • Al Tawalbeh D, Aburjai T, Al Balas Q, Al Samydai A (2022) In silico and in vitro investigation of anti Helicobacter pylori activity of selected phytochemicals. Journal of Pharmacy and Bioallied Sciences 14(3): 132–139. https://doi.org/10.4103/jpbs.jpbs_850_21
  • Alamsyah R, Satari MH, Pintauli S, Iskandar S (2023) Molecular docking analysis of ginger (Zingiber officinale) on dopamine compare to bupropion as smoking cessation. Pharmacia 70(4): 847–852. https://doi.org/10.3897/pharmacia.70.e111049
  • Cardos IA, Danila C, Yahya G, Seleem NM, Mosbah RA, Shaldam MA, Vicas SI, Metwally K, Cavalu SD (2026) Targeting Helicobacter pylori enzymes using Viscum album L. Extract: In silico molecular docking and in vitro study. Frontiers in Cellular and Infection Microbiology 15: 1690969. https://doi.org/10.3389/fcimb.2025.1690969
  • Chen S, Shen W, Liu Y, Dong Q, Shi Y (2023) Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: a randomized controlled trial. Chinese Medical Journal 136(14): 1690–1698. https://doi.org/10.1097/CM9.0000000000002696
  • Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC (2024) ACG clinical guideline: treatment of Helicobacter pylori infection. American Journal of Gastroenterology 119(9): 1730–1753. https://doi.org/10.14309/ajg.0000000000002968
  • Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 7(1): 42717. https://doi.org/10.1038/srep42717
  • Fakih TM, Hikmawati D, Sutedja E, Dwiyana RF, Atik N, Muchtaridi M (2024) In silico investigation of potential Interleukin-8 (IL-8) and Cathelicidin (LL-37) inhibitors for rosacea treatment. Pharmacia 71: 1–12. https://doi.org/10.3897/pharmacia.71.e124099
  • Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK (2016) The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151(1): 51–69.e14. https://doi.org/10.1053/j.gastro.2016.04.006
  • Fong P, Hao C-H, Io C-C, Sin P-I, Meng L-R (2019) In silico and in vitro anti-Helicobacter pylori effects of combinations of phytochemicals and antibiotics. Molecules 24(19): 3608. https://doi.org/10.3390/molecules24193608
  • Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein–ligand docking and virtual drug screening with the autodock suite. Nature Protocols 11(5): 905–919. https://doi.org/10.1038/nprot.2016.051
  • Gao L, Jiang X, Duan H, Shen Y, Gu K, Huang K, Wang Y, Shu M, Zhang R, Lin Z (2024) molecular dynamics simulation-driven focused virtual screening and experimental validation of fisetin as an inhibitor of Helicobacter pylori HtrA protease. https://doi.org/10.21203/rs.3.rs-5316707/v1
  • Guo X, Zhao X, Lu X, Zhao L, Zeng Q, Chen F, Zhang Z, Xu M, Feng S, Fan T, Wei W, Zhang X, Pang J, You X, Song D, Wang Y, Jiang J (2024) A Deep Learning-Driven Discovery of Berberine Derivatives as Novel Antibacterial against Multidrug-Resistant Helicobacter Pylori. Signal Transduction and Targeted Therapy 9(1): 183. https://doi.org/10.1038/s41392-024-01895-0
  • Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC (2017) Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153(2): 420–429. https://doi.org/10.1053/j.gastro.2017.04.022
  • Hu Q, Peng Z, Li L, Zou X, Xu L, Gong J, Yi P (2020) The efficacy of berberine-containing quadruple therapy on Helicobacter pylori eradication in China: a systematic review and meta-analysis of randomized clinical trials. Frontiers in Pharmacology 10: 1694. https://doi.org/10.3389/fphar.2019.01694
  • International Agency for Research on Cancer (1994) 61 Schistosomes, Liver Flukes and Helicobacter Pylori. Lyon: IARC.
  • Ivanov SM (2026a) An efficient computational chemistry approach to generating negative data for drug discovery pipeline validation. Frontiers in Bioinformatics 6: 1756279. https://doi.org/10.3389/fbinf.2026.1756279
  • Kanji S, Mondal S (2024) In silico exploration for potent phytochemicals targeting Helicobacter pylori: Assessment of ADMET Profiles and Molecular Docking Analysis. Discover Chemistry 1(1): 21. https://doi.org/10.1007/s44371-024-00028-4
  • Katelaris P, Hunt R, Bazzoli F, Cohen H, Fock KM, Gemilyan M, Malfertheiner P, Mégraud F, Piscoya A, Quach D, Vakil N, Vaz Coelho LG, LeMair A, Melberg J (2023) Helicobacter pylori world gastroenterology organization global guideline. Journal of Clinical Gastroenterology 57(2): 111–126. https://doi.org/10.1097/MCG.0000000000001719
  • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The Article Was Originally Published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Advanced Drug Delivery Reviews 46(1–3): 3–26. https://doi.org/10.1016/S0169-409X(00)00129-0
  • Liu Y, Yang X, Gan J, Chen S, Xiao Z-X, Cao Y (2022) CB-Dock2: improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Research 50(W1): W159–164. https://doi.org/10.1093/nar/gkac394
  • Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O’Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM (2022) Management of Helicobacter pylori infection: The maastricht VI/Florence consensus report. Gut: gutjnl-2022-327745. https://doi.org/10.1136/gutjnl-2022-327745
  • Musfiroh I, Megawati G, Herawati DMD, Putra ON, Nurrasjid ES (2023) Molecular dynamic of Omega-3 compounds as an anti-obesity agent into GPR-120 receptor. Pharmacia 70(4): 1541–1548. https://doi.org/10.3897/pharmacia.70.e115501
  • Noori Goodarzi N, Khazani Asforooshani M, Shahbazi B, Rezaie Rahimi N, Badmasti F (2024) Identification of novel drug targets for Helicobacter pylori: structure-based virtual screening of potential inhibitors against DAH7PS protein involved in the shikimate pathway. Frontiers in Bioinformatics 4: 1482338. https://doi.org/10.3389/fbinf.2024.1482338
  • Ramadhan DSF, Susanti R, Tjahjono DH, Soe KK, Akbar NH, Fakih TM, Tee YS, Tang HC, Chen H (2026) Homology modeling, pharmacophore-guided virtual screening, molecular docking, and dynamics study of potential allosteric inhibitors targeting EGFR triple resistance mutations (L858R/T790M/L718Q). Pharmacia 73: e182372. https://doi.org/10.3897/pharmacia.73.e182372
  • Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E (2018) Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology 155(5): 1372-1382.e17. https://doi.org/10.1053/j.gastro.2018.07.007
  • Shah SC, Piazuelo MB, Kuipers EJ, Li D (2021) AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology 161(4): 1325–1332.e7. https://doi.org/10.1053/j.gastro.2021.06.078
  • Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P (2015) Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64(9): 1353–1367. https://doi.org/10.1136/gutjnl-2015-309252
  • Sugano K, Moss SF, Kuipers EJ (2023) Gastric intestinal metaplasia: real culprit or innocent bystander as a precancerous condition for gastric cancer? Gastroenterology 165(6): 1352–1366.e1. https://doi.org/10.1053/j.gastro.2023.08.028
  • Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 31(2): 455–461. https://doi.org/10.1002/jcc.21334
  • Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001) Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine 345(11): 784–789. https://doi.org/10.1056/NEJMoa001999
  • Valenzuela-Hormazabal P, Sepúlveda RV, Alegría-Arcos M, Valdés-Muñoz E, Rojas-Pérez V, González-Bonet I, Suardíaz R, Galarza C, Morales N, Leddermann V, Castro RI, Benso B, Urra G, Hernández-Rodríguez EW, Bustos D (2024) Unveiling novel urease inhibitors for Helicobacter pylori: A multi-methodological approach from virtual screening and ADME to molecular dynamics simulations. International Journal of Molecular Sciences 25(4): 1968. https://doi.org/10.3390/ijms25041968
  • Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry 45(12): 2615–2623. https://doi.org/10.1021/jm020017n
  • Wroblewski LE, Peek RM, Wilson KT (2010) Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clinical Microbiology Reviews 23(4): 713–739. https://doi.org/10.1128/CMR.00011-10
  • Yang X, Wang Y, Li L, Tang D, Yan Z, Li M, Jiang J, Bi D (2025) Berberine and its nanoformulations and extracts: potential strategies and future perspectives against multi-drug resistant bacterial infections. Frontiers in Microbiology 16: 1643409. https://doi.org/10.3389/fmicb.2025.1643409
  • Zhang D, Ke L, Ni Z, Chen Y, Zhang LH, Zhu SH, Li CJ, Shang L, Liang J, Shi YQ (2017) Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. Medicine 96(32): e7697. https://doi.org/10.1097/MD.0000000000007697

Additional information

Conflict of interest

The authors have declared that no competing interests exist.

Ethical statements

The authors declared that no clinical trials were used in the present study.

The authors declared that no experiments on humans or human tissues were performed for the present study.

The authors declared that no informed consent was obtained from the humans, donors or donors’ representatives participating in the study.

The authors declared that no experiments on animals were performed for the present study.

The authors declared that no commercially available immortalised human and animal cell lines were used in the present study.

Artificial Intelligence (AI) use

The authors accept full responsibility for the content of the manuscript, including the disclosure of any use of AI.

No AI tools were used in the preparation of this manuscript.

Funding

This study was funded by University of Oradea, Romania.

Author contributions

Conceptualization: C.D. and S.C.; methodology: C.D. and L.F.; manuscript writing and critical revision: C.D., S.C., L.F., and L.M.

Author ORCIDs

C. Danila https://orcid.org/0000-0002-7869-8969

L. Faur https://orcid.org/0000-0002-4953-1350

L. Mocan https://orcid.org/0000-0002-7444-7978

D.S. Cavalu https://orcid.org/0000-0001-7810-8925

Data availability

Docking score matrices, interaction summaries, ADMET descriptor tables, and figure files can be provided by the corresponding author upon reasonable request.

login to comment